Understanding how TMPRSS2-ERG fusion and p53 inactivation contribute to prostate cancer
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-11062411
This study is looking at how certain gene changes might help prostate cancer grow and spread, using information from over 1500 patients to find new ways to improve diagnosis and treatment for men with this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11062411 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the TMPRSS2-ERG gene fusion and the inactivation of the p53 tumor suppressor gene in the development and progression of prostate cancer. By analyzing genetic data from over 1500 prostate cancer patient specimens, the study aims to uncover how these genetic alterations cooperate to drive cancer pathogenesis. The research utilizes advanced techniques, including next-generation sequencing, to explore the molecular mechanisms involved, which could lead to new therapeutic targets. Patients may benefit from insights that could improve diagnosis and treatment strategies for prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with advanced prostate cancer, particularly those with TMPRSS2-ERG fusion and p53 inactivation.
Not a fit: Patients without prostate cancer or those whose cancer does not involve TMPRSS2-ERG fusion or p53 inactivation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and personalized therapies for prostate cancer patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of genetic alterations in prostate cancer, indicating that this approach has potential for significant findings.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, LIEWEI — MAYO CLINIC ROCHESTER
- Study coordinator: WANG, LIEWEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced prostate cancer, anti-cancer